David Rodman’s Smart Stock Move | Business and Finance News

David Rodman, Mineralys Therapeutics’ chief medical officer, cashed in over $557K by selling 20K shares he’d exercised via stock options in July 2026 — a savvy move that locked in profits while still leaving him heavily invested in the company’s future. With the firm’s stock up nearly 90% in a year and a major FDA milestone looming in December, Rodman’s sale was part of a pre-approved trading plan designed to avoid insider trading concerns, showcasing how insiders can profit strategically without jeopardizing the company’s mission to bring new hypertension treatments to market. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/fa2b4cfb0ad7ca31